ArticleBMC neurology2025
Validation of dementia-free status in the iranian brain imaging database using ADNI data: a transition point from middle age to older adulthood.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo validate the Iranian Brain Imaging Database (IBID) for dementia-free status in middle-aged to older adults (over 55 years old) by comparing dementia probability metrics with Alzheimer's disease (AD) patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
methodsThis cross-sectional study included 41 cognitively normal participants from IBID (age > 55 years; median (IQR) = 64 (62, 68) years; females = 51.2%) and 41 age/sex-matched AD patients from ADNI (age > 55 years; median (IQR) = 69 (62, 71) years; females = 53.7%). High-resolution 3D T1-weighted MPRAGE MRI data were harmonized across Siemens 3.0 Tesla scanners, preprocessed via the AssemblyNet-AD pipeline (volBrain), and analyzed for grading scores and hippocampal-amygdalo-ventricular atrophy scores (HAVAs), along with hippocampus, amygdala, and inferior lateral ventricle atrophy scores. Non-parametric Mann-Whitney U tests were used to compare group differences, and quantile regression (25th, 50th, and 75th quantiles) model atrophy severity-dependent associations.
resultsIBID participants exhibited minimal dementia probability (median grading score = 0.20% vs. ADNI = 99.93%; U = 84.0, p < 0.0001) and markedly lower atrophy across all regions (HAVAs: 14.76 vs. 86.41; U = 75.0, p < 0.0001), with non-overlapping interquartile ranges. Quantile regression revealed stable hippocampal contributions (q₀.₅ coefficient = 0.311, p < 0.001) and increasing group disparities at higher atrophy severities (q₀.₇₅: IBID vs. ADNI coefficient = - 11.82, p < 0.001).
conclusionWe provided validated dementia-free IBID neuroimaging data to distinguish normal aging from dementia-AD status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.